Search Results - "STURIS, JEPPE"

Elucidating the Mechanism of Absorption of Fast-Acting Insulin Aspart: The Role of Niacinamide by Kildegaard, Jonas, Buckley, Stephen T., Nielsen, Rasmus H., Povlsen, Gro K., Seested, Torben, Ribel, Ulla, Olsen, Helle B., Ludvigsen, Svend, Jeppesen, Claus B., Refsgaard, Hanne H. F., Bendtsen, Kristian M., Kristensen, Niels R., Hostrup, Susanne, Sturis, Jeppe

“…Purpose Fast-acting insulin aspart (faster aspart) is a novel formulation of insulin aspart containing two additional excipients: niacinamide, to increase…”
Get full text

Enhanced disulphide bond stability contributes to the once-weekly profile of insulin icodec by Hubálek, František, Cramer, Christian N., Helleberg, Hans, Johansson, Eva, Nishimura, Erica, Schluckebier, Gerd, Steensgaard, Dorte Bjerre, Sturis, Jeppe, Kjeldsen, Thomas B.

“…Insulin icodec is a once-weekly insulin analogue that has a long half-life of approximately 7 days, making it suitable for once weekly dosing. The Insulin…”
Get full text

A novel high-affinity peptide antagonist to the insulin receptor by Schäffer, Lauge, Brand, Christian L., Hansen, Bo F., Ribel, Ulla, Shaw, Allan C., Slaaby, Rita, Sturis, Jeppe

“…In this publication we describe a peptide insulin receptor antagonist, S661, which is a single chain peptide of 43 amino acids. The affinity of S661 for the…”
Get full text

One Week’s Treatment With the Long-Acting Glucagon-Like Peptide 1 Derivative Liraglutide (NN2211) Markedly Improves 24-h Glycemia and α- and β-Cell Function and Reduces Endogenous Glucose Release in Patients with Type 2 Diabetes by DEGN, Kristine B, JUHL, Claus B, STURIS, Jeppe, JAKOBSEN, Grethe, BROCK, Birgitte, CHANDRAMOULI, Visvanathan, RUNGBY, Joergen, LANDAU, Bernard R, SCHMITZ, Ole

“…One Week’s Treatment With the Long-Acting Glucagon-Like Peptide 1 Derivative Liraglutide (NN2211) Markedly Improves 24-h Glycemia and α- and β-Cell Function…”
Get full text

Small-molecule agonists for the glucagon-like peptide 1 receptor by Knudsen, Lotte Bjerre, Kiel, Dan, Teng, Min, Behrens, Carsten, Bhumralkar, Dilip, Kodra, János T, Holst, Jens J, Jeppesen, Claus B, Johnson, Michael D, de Jong, Johannes Cornelis, Jorgensen, Anker Steen, Kercher, Tim, Kostrowicki, Jarek, Madsen, Peter, Olesen, Preben H, Petersen, Jacob S, Poulsen, Fritz, Sidelmann, Ulla G, Sturis, Jeppe, Truesdale, Larry, May, John, Lau, Jesper

“…The peptide hormone glucagon-like peptide (GLP)-1 has important actions resulting in glucose lowering along with weight loss in patients with type 2 diabetes…”
Get full text

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of a Single-Dose of NN2211, a Long-Acting Glucagon-Like Peptide 1 Derivative, in Healthy Male Subjects by ELBRØND, Bodil, JAKOBSEN, Grethe, LARSEN, Søren, AGERSØ, Henrik, JENSEN, Lisbeth Bjerring, ROLAN, Paul, STURIS, Jeppe, HATORP, Vibeke, ZDRAVKOVIC, Milan

“…Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of a Single-Dose of NN2211, a Long-Acting Glucagon-Like Peptide 1 Derivative, in Healthy Male…”
Get full text

Bedtime Administration of NN2211, a Long-Acting GLP-1 Derivative, Substantially Reduces Fasting and Postprandial Glycemia in Type 2 Diabetes by JUHL, Claus B, HOLLINGDAL, Malene, STURIS, Jeppe, JAKOBSEN, Grethe, AGERSØ, Henrik, VELDHUIS, Johannes, PØRKSEN, Niels, SCHMITZ, Ole

“…Bedtime Administration of NN2211, a Long-Acting GLP-1 Derivative, Substantially Reduces Fasting and Postprandial Glycemia in Type 2 Diabetes Claus B. Juhl 1 ,…”
Get full text

The GLP-1 Derivative NN2211 Restores β-Cell Sensitivity to Glucose in Type 2 Diabetic Patients After a Single Dose by CHANG, Annette M, JAKOBSEN, Grethe, STURIS, Jeppe, SMITH, Marla J, BLOEM, Cathie J, AN, Bob, GALECKI, Andrzej, HALTER, Jeffrey B

“…The GLP-1 Derivative NN2211 Restores β-Cell Sensitivity to Glucose in Type 2 Diabetic Patients After a Single Dose Annette M. Chang 1 , Grethe Jakobsen 2 ,…”
Get full text

Estimation of insulin secretion rates from C-peptide levels : comparison of individual and standard kinetic parameters for C-peptide clearance by CAUTER, E. V, MESTREZ, F, STURIS, J, POLONSKY, K. S

“…Insulin secretion rates can be accurately estimated from plasma C-peptide levels with a two-compartment model for C-peptide distribution and degradation. In…”
Get full text

Probing the mechanism of reduced in vivo potency of insulin detemir by Brand, Christian Lehn, Sturis, Jeppe

“…Insulin detemir (IDet) is an insulin analog used to treat diabetes. IDet shows full efficacy but reduced potency compared to human insulin (HI) in both man and…”
Get more information

NN414, a SUR1/Kir6.2-Selective Potassium Channel Opener, Reduces Blood Glucose and Improves Glucose Tolerance in the VDF Zucker Rat by CARR, Richard D, BRAND, Christian L, BODVARSDOTTIR, Thora B, HANSEN, John B, STURIS, Jeppe

“…NN414, a SUR1/Kir6.2-Selective Potassium Channel Opener, Reduces Blood Glucose and Improves Glucose Tolerance in the VDF Zucker Rat Richard D. Carr 1 ,…”
Get full text

Improved β-Cell Survival and Reduced Insulitis in a Type 1 Diabetic Rat Model After Treatment With a β-Cell–Selective KATP Channel Opener by SKAK, Kresten, GOTFREDSEN, Carsten F, LUNDSGAARD, Dorthe, HANSEN, John Bondo, STURIS, Jeppe, MARKHOLST, Helle

“…Improved β-Cell Survival and Reduced Insulitis in a Type 1 Diabetic Rat Model After Treatment With a β-Cell–Selective K ATP Channel Opener Kresten Skak 1 ,…”
Get full text

Continuous Glucose Monitoring Sensor Glucose Levels and Insulin Pump Infusion Set Wear-Time During Treatment with Fast-Acting Insulin Aspart: A Post Hoc Analysis of Onset 5 by Gorst-Rasmussen, Anders, Sturis, Jeppe, Ekelund, Magnus

“…In the onset 5 trial, fast-acting insulin aspart (faster aspart) was noninferior to insulin aspart (IAsp) for change from baseline glycated hemoglobin at 16…”
Get more information

2032-LB: In Vivo Chain Splitting of Human Insulin by Sturis, Jeppe, Cramer, Christian, Brand, Christian L, Helleberg, Hans, Kurtzhals, Peter, Hubalek, Frantisek

“…Non-insulin receptor-mediated insulin degradation via insulin degrading enzyme has been proposed to play a role in insulin resistance (IR). Recently,…”
Get full text

Commemorating insulin's centennial: engineering insulin pharmacology towards physiology by Kurtzhals, Peter, Nishimura, Erica, Haahr, Hanne, Høeg-Jensen, Thomas, Johansson, Eva, Madsen, Peter, Sturis, Jeppe, Kjeldsen, Thomas

“…The life-saving discovery of insulin in Toronto in 1921 is one of the most impactful achievements in medical history, at the time being hailed as a miracle…”
Get full text

815-P: Enhanced Disulphide Bond Stability Contributes to the Once Weekly PD Profile of Insulin Icodec by HUBALEK, FRANTISEK, CRAMER, CHRISTIAN, HELLEBERG, HANS, JOHANSSON, EVA, SCHLUCKEBIER, GERD, STEENSGAARD, DORTE B., STURIS, JEPPE, KJELDSEN, THOMAS

“…Insulin icodec is a novel basal insulin analogue with a long half-life (196 hours) that is in clinical development for the treatment of diabetes with once…”
Get full text

381-P: Recurrent Hypoglycemia Alters Endocrine Counterregulation during Insulin-Induced Hypoglycemia in Healthy and Diabetic Göttingen Minipigs by LYHNE, MILLE KRONBORG, HINZ, KATHRIN, VEGGE, ANDREAS, STURIS, JEPPE, KILDEGAARD, JONAS, PEDERSEN-BJERGAARD, ULRIK, OLSEN, LISBETH HØIER

“…Hypoglycemia is a common adverse effect of insulin treatment in people with diabetes and recurrent episodes can alter counter regulation, ultimately increasing…”
Get full text

Sleepiness, performance, and neuroendocrine function during sleep deprivation: effects of exposure to bright light or exercise by Leproult, R, Van Reeth, O, Byrne, M M, Sturis, J, Van Cauter, E

“…The temporal profiles of subjective fatigue (as assessed by the Stanford Sleepiness Scale), of cognitive performance (on a digit symbol substitution test and a…”
Get more information

Factors Affecting Performance of Insulin Pen Injector Technology: A Narrative Review by Sparre, Thomas, Hammershøy, Laura, Steensgaard, Dorte Bjerre, Sturis, Jeppe, Vikkelsøe, Per, Azzarello, Antonino

“…Background: Insulin treatment is an essential hormone replacement therapy for the survival of people with type 1 diabetes and is often used for treatment in…”
Get full text

Glucose- and Interleukin-1β-Induced β-Cell Apoptosis Requires Ca2+ Influx and Extracellular Signal-Regulated Kinase (ERK) 1/2 Activation and Is Prevented by a Sulfonylurea Receptor 1/Inwardly Rectifying K+ Channel 6.2 (SUR/Kir6.2) Selective Potassium Channel Opener in Human Islets by MAEDLER, Kathrin, STØRLING, Joachim, STURIS, Jeppe, ZUELLIG, Richard A, SPINAS, Giatgen A, ARKHAMMAR, Per O. G, MANDRUP-POULSEN, Thomas, DONATH, Marc Y

“…Glucose- and Interleukin-1β-Induced β-Cell Apoptosis Requires Ca 2+ Influx and Extracellular Signal-Regulated Kinase (ERK) 1/2 Activation and Is Prevented by a…”
Get full text